United States Gastric Cancer Diagnostic Procedure Market

Historic Data: 2020-2021   |   Base Year: 2022   |   Forecast Period: 2023-2028

Analysis by Healthcare Providers (Diagnostic Laboratories, Hospitals, Cancer Research Institutes, Oncology Specialty Clinics, and Others), Symptom Types (Symptomatic and Asymptomatic), Body Fluid (Blood, Urine, Saliva, Stomach Wash/Gastric Juice, Tissue, and Others), Procedures (Endoscopic Procedures, Biopsy & Tissue Tests, Lab Tests, In-Vitro Diagnostic Tests, Imaging Tests, Molecular Diagnostics, Multiplexing Molecular Diagnostics & Immunoassays, and Others), Offerings (Instruments, Reagents & Consumables, and Services), and Disease Indication (Early Gastric Cancer and Advanced Gastric Cancer)


No. of Pages: 158    |    Report Code: BMIRE00028016    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Buy Now
United States Gastric Cancer Diagnostic Procedure Market

The United States gastric cancer diagnostic procedure market size is expected to reach US$ 637.84 million by 2028 from   in 2022. The market is estimated to record a CAGR of 4.8% from 2022 to 2028.

 

 The rising prevalence of gastrointestinal diseases and the growing geriatric population in the US are contributing to the growth of the United States gastric cancer diagnostic procedure market size. However, the shortage of medical laboratory professionals is hampering the market growth.

 

Rising Geriatric Population in US Drives United States Gastric Cancer Diagnostic Procedure Market Growth

 

As per the Fact Sheet: Aging in the United States, the number of people aged 65 and above is estimated to increase from 52 million in 2018 to 95 million by 2060. Additionally, the 65-year-old age group’s share of the total population will increase from 16% in 2018 to 23% by 2060. Further, as per the US Census Bureau, all the baby boomers will be older than 65 years in the US by 2030 and will hold 21% of the population. It also mentioned that by 2060, around one in four people in the US will be aged 65 years and above, the number of people aged 85 and above will triple, and the country will add half a million centenarians. The prevalence of gastrointestinal disorders is high in the adult and elderly populations. As the aging population rises, the disease burden also increases. Thus, an increasing aging population propels the demand for gastric cancer diagnostics, thereby bolstering the growth of the gastric cancer diagnostic procedure market.

 

Based on symptom type, the United States gastric cancer diagnostic procedure market is bifurcated into symptomatic and asymptomatic. The asymptomatic segment held a larger share of the market in 2022. However, the symptomatic segment is anticipated to register a higher CAGR in the market during the forecast period. The symptoms of the early stages of gastric cancer may include indigestion, stomach discomfort, bloating, mild nausea, appetite loss, and heartburn. The advanced stages of gastric cancer show symptoms such as blood in the stool, vomiting, weight loss, stomach pain, jaundice, ascites (build-up of fluid in the abdomen), and trouble swallowing. Based on healthcare providers, the market is segmented into diagnostic laboratories, hospitals, cancer research institutes, oncology specialty clinics, others. In 2022, the hospitals segment held the largest share of the United States gastric cancer diagnostic procedure market. The market for the cancer research institutes segment is expected to grow at the highest rate in the coming years. The United States gastric cancer diagnostic procedure market, by body fluid, is segmented into blood, urine, saliva, stomach wash/gastric juice, tissue, and others. In 2021, the blood segment held the largest share of the market. However, the market for the tissue segment is expected to grow at the highest rate in the coming years. The United States gastric cancer diagnostic procedure market, based on procedures, is segmented into endoscopic procedures, biopsy and tissue tests, lab tests, in-vitro diagnostic tests, imaging tests, molecular diagnostics, multiplexing molecular diagnostics and immunoassays, and others. In 2021, the imaging tests segment held the largest share of the market. The market for the biopsy and tissue tests segment is expected to grow at the highest rate in the coming years. The United States gastric cancer diagnostic procedure market, based on offerings, is segmented into instruments, reagents and consumables, and services. In 2021, the reagents and consumables segment held the largest share of the market. The market for the services segment is expected to grow at the highest rate in the coming years. The United States gastric cancer diagnostic procedure market, based on disease indication, is segmented into early gastric cancer and advanced gastric cancer. In 2021, the advanced gastric cancer segment held a larger share of the market. The market for the same segment is expected to grow at a higher rate in the coming years.

 

The International Foundation for Gastrointestinal Disorders, American Institute for Cancer Research, Centers for Disease Control and Prevention, U.S. Census Bureau, and Population Reference Bureau are among the major primary and secondary sources referred to while preparing the report on the United States gastric cancer diagnostic procedure market.


United States Gastric Cancer Diagnostic Procedure Strategic Insights

Strategic insights for the United States Gastric Cancer Diagnostic Procedure provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

strategic-framework/united-states-gastric-cancer-diagnostic-procedure-market-strategic-framework.webp
Get more information on this report

United States Gastric Cancer Diagnostic Procedure Report Scope

Report Attribute Details
Market size in 2022 US$ XX Million
Market Size by 2028 US$ 637.84 Million
Global CAGR (2022 - 2028) 4.8%
Historical Data 2020-2021
Forecast period 2023-2028
Segments Covered By Healthcare Providers
  • Diagnostic Laboratories
  • Hospitals
  • Cancer Research Institutes
  • Oncology Specialty Clinics
By Symptom Types
  • Symptomatic and Asymptomatic
By Body Fluid
  • Blood
  • Urine
  • Saliva
  • Stomach Wash/Gastric Juice
  • Tissue
By Procedures
  • Endoscopic Procedures
  • Biopsy & Tissue Tests
  • Lab Tests
  • In-Vitro Diagnostic Tests
  • Imaging Tests
  • Molecular Diagnostics
  • Multiplexing Molecular Diagnostics & Immunoassays
By Offerings
  • Instruments
  • Reagents & Consumables
  • Services
Regions and Countries Covered United States
  • United States
Market leaders and key company profiles
  • Atlas-Link Biotech Co Ltd
  • Bio-Rad Laboratories Inc
  • MiRXES Pte Ltd
  • Agilent Technologies Inc
  • F. Hoffmann-La Roche Ltd
  • bioMerieux SA
  • Thermo Fisher Scientific Inc
  • Illumina Inc
  • Vela Diagnostics Holding Pte Ltd
  • Myraid Genetics Inc.
  • Get more information on this report

    United States Gastric Cancer Diagnostic Procedure Regional Insights

    The geographic scope of the United States Gastric Cancer Diagnostic Procedure refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

    geography/united-states-gastric-cancer-diagnostic-procedure-market-geography.webp
    Get more information on this report

    The List of Companies - United States Gastric Cancer Diagnostic Procedure Market

    1. Atlas-Link Biotech Co Ltd
    2. Bio-Rad Laboratories Inc
    3. MiRXES Pte Ltd
    4. Agilent Technologies Inc
    5. F. Hoffmann-La Roche Ltd
    6. bioMerieux SA
    7. Thermo Fisher Scientific Inc
    8. Illumina Inc
    9. Vela Diagnostics Holding Pte Ltd
    10. Myraid Genetics Inc.
    Frequently Asked Questions
    How big is the United States Gastric Cancer Diagnostic Procedure Market?

    The United States Gastric Cancer Diagnostic Procedure Market is valued at US$ XX Million in 2022, it is projected to reach US$ 637.84 Million by 2028.

    What is the CAGR for United States Gastric Cancer Diagnostic Procedure Market by (2022 - 2028)?

    As per our report United States Gastric Cancer Diagnostic Procedure Market, the market size is valued at US$ XX Million in 2022, projecting it to reach US$ 637.84 Million by 2028. This translates to a CAGR of approximately 4.8% during the forecast period.

    What segments are covered in this report?

    The United States Gastric Cancer Diagnostic Procedure Market report typically cover these key segments-

    • Healthcare Providers (Diagnostic Laboratories, Hospitals, Cancer Research Institutes, Oncology Specialty Clinics)
    • Symptom Types (Symptomatic and Asymptomatic)
    • Body Fluid (Blood, Urine, Saliva, Stomach Wash/Gastric Juice, Tissue)
    • Procedures (Endoscopic Procedures, Biopsy & Tissue Tests, Lab Tests, In-Vitro Diagnostic Tests, Imaging Tests, Molecular Diagnostics, Multiplexing Molecular Diagnostics & Immunoassays)
    • Offerings (Instruments, Reagents & Consumables, Services)

    What is the historic period, base year, and forecast period taken for United States Gastric Cancer Diagnostic Procedure Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the United States Gastric Cancer Diagnostic Procedure Market report:

  • Historic Period : 2020-2021
  • Base Year : 2022
  • Forecast Period : 2023-2028
  • Who are the major players in United States Gastric Cancer Diagnostic Procedure Market?

    The United States Gastric Cancer Diagnostic Procedure Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • Atlas-Link Biotech Co Ltd
  • Bio-Rad Laboratories Inc
  • MiRXES Pte Ltd
  • Agilent Technologies Inc
  • F. Hoffmann-La Roche Ltd
  • bioMerieux SA
  • Thermo Fisher Scientific Inc
  • Illumina Inc
  • Vela Diagnostics Holding Pte Ltd
  • Myraid Genetics Inc.
  • Who should buy this report?

    The United States Gastric Cancer Diagnostic Procedure Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the United States Gastric Cancer Diagnostic Procedure Market value chain can benefit from the information contained in a comprehensive market report.